Irexime (Clindamycin, Benzoyl Peroxide)

Clindamycin inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit of Propionibacterium acnes. This action stops the bacteria from multiplying, reducing the bacterial load on the skin and consequently decreasing inflammation associated with acne lesions.

The dosage regimen for Irexime is determined by the prescribing healthcare professional. Typically, a thin layer is applied to the affected skin once or twice daily, but the exact frequency and duration depend on the severity of acne and the patient’s response to therapy.

Safety data for clindamycin and benzoyl peroxide in pregnancy and lactation are limited. Women who are pregnant, planning to become pregnant, or breastfeeding should discuss potential risks and benefits with their physician before using Irexime.

To order Irexime, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

Irexime combines an antibiotic (clindamycin) with a keratolytic (benzoyl peroxide), offering both antibacterial and comedolytic actions in a single product. Compared with monotherapy options such as topical retinoids or oral antibiotics, the combination can provide faster lesion reduction and lower the risk of antibiotic resistance when used as directed.

Store Irexime at temperatures below 25 °C in its original packaging. Keep the container tightly closed, protect it from moisture and direct sunlight, and avoid freezing. Proper storage helps maintain product stability and efficacy.

Apply a thin, even layer of Irexime to clean, dry skin on the affected areas, usually once or twice daily as prescribed. Wash hands before and after application, and avoid contact with eyes, lips and mucous membranes. Do not cover the treated skin with occlusive dressings unless instructed by a clinician.

Serious adverse reactions, although rare, include severe contact dermatitis, extensive skin irritation, and allergic responses such as swelling, blistering or urticaria. If any of these occur, discontinue use immediately and seek medical attention.

Irexime should be avoided by individuals with known hypersensitivity to clindamycin, benzoyl peroxide, or any component of the formulation. It is also contraindicated on severely damaged, inflamed or infected skin, and should not be used on the face of patients with a history of severe allergic reactions to similar topical agents.